Comprehensive analysis of glomerular mRNA expression of pro- and antithrombotic genes in atypical haemolytic-uremic syndrome (aHUS)

Virchows Arch. 2013 Apr;462(4):455-64. doi: 10.1007/s00428-013-1386-4. Epub 2013 Mar 9.

Abstract

Atypical haemolytic-uremic syndrome (aHUS) is, in most cases, due to hereditary or acquired defects in complement regulation and a life-threatening disease. Despite the rapidly grown knowledge about the primary defects in aHUS, the pathogenesis that links complement dysregulation with microthrombus formation in aHUS is still unknown. Thus, we examined the glomerular microvascular expression of pro- and antithrombotic genes. Glomeruli were microdissected from 12 archival paraffin-embedded biopsies with aHUS and from seven control biopsies. Glomerular mRNA expression was quantified by single real-time PCR reactions after preamplification. In addition immunostains were performed for plasminogen activator inhibitor 1 (PAI-1) and for tissue plasminogen activator (tPA). Results were compared between cases and controls and with clinical data. Glomeruli in aHUS had increased mRNA expression of antifibrinolytic, prothrombotic PAI-1, antithrombotic thrombomodulin (THBD) and CD73 and decreased expression of profibrinolytic, antithrombotic tPA compared to controls. Impaired fibrinolysis due to increased microvascular expression of the antifibrinolytic PAI-1 in combination with the decreased expression of the profibrinolytic tPA seems to be a final common pathway in renal thrombotic microangiopathy that is also effective in aHUS. The concomitant induction of antithrombotic transcripts likely indicates counterregulatory efforts, demonstrating that the capillary bed is not a passive victim of complement attack. Future research should investigate if and how complement activation could induce the reported shift in the expression of PAI-1 and tPA.

MeSH terms

  • ADAM Proteins / genetics
  • ADAMTS13 Protein
  • Adult
  • Atypical Hemolytic Uremic Syndrome
  • Female
  • Hemolytic-Uremic Syndrome / metabolism*
  • Hemolytic-Uremic Syndrome / pathology
  • Humans
  • Kidney Glomerulus / metabolism*
  • Kruppel-Like Transcription Factors / genetics
  • Male
  • Middle Aged
  • Plasminogen Activator Inhibitor 1 / analysis
  • Plasminogen Activator Inhibitor 1 / genetics*
  • RNA, Messenger / analysis*
  • Tissue Plasminogen Activator / analysis
  • Tissue Plasminogen Activator / genetics*

Substances

  • KLF2 protein, human
  • Kruppel-Like Transcription Factors
  • Plasminogen Activator Inhibitor 1
  • RNA, Messenger
  • Tissue Plasminogen Activator
  • ADAM Proteins
  • ADAMTS13 Protein
  • ADAMTS13 protein, human